BRPI0910476A2 - composições de vacinas para tratamento de febre do dengue e seus usos - Google Patents

composições de vacinas para tratamento de febre do dengue e seus usos

Info

Publication number
BRPI0910476A2
BRPI0910476A2 BRPI0910476A BRPI0910476A BRPI0910476A2 BR PI0910476 A2 BRPI0910476 A2 BR PI0910476A2 BR PI0910476 A BRPI0910476 A BR PI0910476A BR PI0910476 A BRPI0910476 A BR PI0910476A BR PI0910476 A2 BRPI0910476 A2 BR PI0910476A2
Authority
BR
Brazil
Prior art keywords
vaccine compositions
dengue fever
fever vaccine
dengue
compositions
Prior art date
Application number
BRPI0910476A
Other languages
English (en)
Inventor
Huber Adrian
Ivanova Lidia
Bachmann Martin
Original Assignee
Cytios Biotechnology Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytios Biotechnology Ag filed Critical Cytios Biotechnology Ag
Publication of BRPI0910476A2 publication Critical patent/BRPI0910476A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18123—Virus like particles [VLP]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0910476A 2008-04-22 2009-04-22 composições de vacinas para tratamento de febre do dengue e seus usos BRPI0910476A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08154974 2008-04-22
PCT/EP2009/054856 WO2009130261A1 (en) 2008-04-22 2009-04-22 Vaccine compositions for the treatment of dengue fever and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0910476A2 true BRPI0910476A2 (pt) 2018-03-27

Family

ID=40872441

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910476A BRPI0910476A2 (pt) 2008-04-22 2009-04-22 composições de vacinas para tratamento de febre do dengue e seus usos

Country Status (9)

Country Link
US (1) US20110262472A1 (pt)
EP (1) EP2280727A1 (pt)
CN (1) CN102014952A (pt)
AU (1) AU2009240011A1 (pt)
BR (1) BRPI0910476A2 (pt)
CA (1) CA2721657A1 (pt)
MX (1) MX2010011373A (pt)
WO (1) WO2009130261A1 (pt)
ZA (1) ZA201007091B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1450856B1 (en) 2001-09-14 2009-11-11 Cytos Biotechnology AG Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use
WO2011080505A2 (en) 2009-12-28 2011-07-07 Bigdna Ltd Method of growing phage for commercial use
US8993744B2 (en) 2010-05-21 2015-03-31 University of Pittsburgh—of the Commonwealth System of Higher Education Universal dengue virus sequences and methods of use
WO2012154202A1 (en) 2010-10-29 2012-11-15 Merck Sharp & Dohme Corp. Recombinant subunit dengue virus vaccine
CN102824633A (zh) * 2011-06-16 2012-12-19 中国人民解放军军事医学科学院微生物流行病研究所 一种四价登革病毒亚单位疫苗及其制备方法和应用
US10526376B2 (en) 2015-01-15 2020-01-07 University Of Copenhagen Virus-like particle with efficient epitope display
EP3368068B1 (en) 2015-10-30 2020-11-18 University of Copenhagen Virus like particle with efficient epitope display
WO2022169665A1 (en) * 2021-02-05 2022-08-11 Unm Rainforest Innovations Bacteriophage virus-like particle vaccines against flavivirus non-structural protein 1
CN115990249B (zh) * 2022-10-10 2025-07-25 中国人民解放军陆军军医大学 一种登革四价dna疫苗及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
EP1572941A4 (en) * 2002-02-26 2009-03-18 Maxygen Inc NEW FLAVIVIRUS ANTIGENES
JP4726483B2 (ja) * 2002-07-17 2011-07-20 サイトス バイオテクノロジー アーゲー 分子抗原アレイ
FR2870126B1 (fr) * 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
MX2007003171A (es) * 2004-09-21 2007-05-23 Cytos Biotechnology Ag Particulas tipo virus que comprenden una proteina de fusion de la proteina de cubierta de ap205 y un polipeptido antigenico.
CN101052411B (zh) * 2004-10-05 2011-04-06 赛托斯生物技术公司 Vlp-抗原偶联物及其作为疫苗的用途

Also Published As

Publication number Publication date
US20110262472A1 (en) 2011-10-27
ZA201007091B (en) 2011-12-28
WO2009130261A1 (en) 2009-10-29
CN102014952A (zh) 2011-04-13
CA2721657A1 (en) 2009-10-29
AU2009240011A1 (en) 2009-10-29
EP2280727A1 (en) 2011-02-09
MX2010011373A (es) 2010-11-12

Similar Documents

Publication Publication Date Title
PT2473528E (pt) Formulações estáveis de polipéptidos e seus usos
BRPI0809103A2 (pt) composições de magnésio e seus usos
BRPI0910746A2 (pt) reticuladores e seus usos
BRPI0921862A2 (pt) inibidores de raf e seus usos
BR112013012190A2 (pt) composições adesivas e seus usos
BRPI0817234A2 (pt) Análogos de azacitidina e seus usos
BRPI0913640A2 (pt) substâncias policrômicas e seus usos
BR112013012132A2 (pt) composição compreendendo proteínas e oligossacarídeos hidrolisados, e seus usos
BRPI0909185A2 (pt) Derivado de vitamina e e seus usos
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos
BR112013012129A2 (pt) composições de adesivos e seus usos
BRPI1008709A2 (pt) composições e usos das mesmas.
BRPI0919881A2 (pt) composições, métodos e usos para arcabouço com base no domínio fibronectina tipo iii
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI0813244A2 (pt) Compostos e seus usos 708
BRPI0911656A2 (pt) formulações de nanopartículas e usos das mesmas
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BR112012004979A2 (pt) composições para o tratamento de semente e métodos
BRPI1014494A2 (pt) vacina pneumocócica e usos da mesma
BRPI0908853A2 (pt) composto oligopeptídicos e seus usos
BRPI0913574A2 (pt) composição de tratamento de acne compreendendo nanoprata e usos
BRPI0920927A2 (pt) derivados de azaquinolinona e usos dos mesmos
BRPI0924103A2 (pt) usos de thaxtomin e composições de thaxtomin como herbicidas
BRPI0906498A2 (pt) Anticorpo ron e seus usos
FI20096058A0 (fi) Koostumuksia ja niihin liittyviä menetelmiä ja käyttöjä

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A, 7A, 8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]